Gilead Sciences Inc. (NASDAQ: GILD) is trading higher this Monday on a top research upgrade. The biotech was raised to the Conviction Buy List by Goldman Sachs. Its new price target is $46.00 per share. Shares are indicated up 1.6% at $39.90 and the 52-week range is $34.45 to $43.49.
Contact [email protected] for any questions or corrections.